Holle Julia U, Vaglio Augusto
Rheumazentrum Schleswig-Holstein Mitte, Neumünster, Germany.
Rheumazentrum Schleswig-Holstein Mitte, Kiel, Germany.
Rheumatology (Oxford). 2025 Mar 1;64(Supplement_1):i92-i97. doi: 10.1093/rheumatology/keae608.
Hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA) both present with hypereosinophilia and organ damage induced by eosinophils. EGPA is also characterized by vasculitis and is associated with ANCA. Yet, discriminating HES from EGPA may be difficult in clinical practice as biomarkers to reliably differentiate between HES and EGPA are still lacking. In recent years, it has been demonstrated that targeting IL-5 is efficacious to treat HES and EGPA, and the use of anti-IL-5(R)-antibodies has become a mainstay of therapy in HES and these diseases. Nonetheless, it remains unclear whether anti-IL-5 strategies are sufficient to treat organ-threatening eosinophilic manifestations or vasculitic manifestations in EGPA.
高嗜酸性粒细胞综合征（HES）和嗜酸性肉芽肿性多血管炎（EGPA）均表现为嗜酸性粒细胞增多以及由嗜酸性粒细胞引起的器官损害。EGPA还具有血管炎特征，且与抗中性粒细胞胞浆抗体（ANCA）相关。然而，在临床实践中区分HES和EGPA可能存在困难，因为目前仍缺乏可靠区分HES和EGPA的生物标志物。近年来，已证明靶向白细胞介素-5（IL-5）治疗HES和EGPA有效，使用抗IL-5（R）抗体已成为HES及这些疾病治疗的主要手段。尽管如此，抗IL-5策略是否足以治疗EGPA中威胁器官的嗜酸性表现或血管炎表现仍不清楚。
